Abstract
The dramatic increase in obesity has put people under increasing pressure. Lipase inhibitors, have received increasing attention from researchers because of their advantages of acting in the intestinal tract and having no side effects on the central nervous system. In this paper, the molecular dynamics, cellular level and zoological model of lipase inhibitors for anti-obesity drug screening and inhibition mechanisms were analysed and discussed. FBT was identified as a mixed reversible inhibitor with an IC 50 of 1.02 ± 0.03 μg/mL. In vitro experiments showed that FBT reduce ROS production and mRNA expression of related inflammatory factors during cell differentiation. In animal experiments, we confirmed that FBT can effectively lessen the level of fatty liver, prevent liver fibrosis and the accumulation of lipid droplets, improve mitochondrial membrane structure damage. The inhibitory mechanism of FBT was discussed to provide a theoretical basis for the screening and clinical treatment of lipase inhibitors. Funding: Supported by Xiamen Municipal Bureau of Science and Technology (3502Z20193006); Postdoctoral Science Foundation of China (2021M691283). Declaration of Interest: The authors declare no conflict of interest. Ethical Approval: The animal experiment was conducted in accordance with the “Laboratory Animal Guideline for Ethical Review of Animal Welfare” (GB/T 35892–1272018) and the Experimental Animal Management and Ethics Committee of Xiamen University (Certificate no. SYXK2013–0006).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.